GlaxoSmithKline (GSK.US) will sell all remaining shares in Haleon (HLN.US)
British pharmaceutical company GlaxoSmithKline announced on Thursday that it plans to sell all of its remaining shares in consumer care company Haleon.
GlaxoSmithKline (GSK) Gets a Buy From Jefferies
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to Reach $4.8 Billion b
Earnings Call Summary | GlaxoSmithKline(GSK.US) Q1 2024 Earnings Conference
The following is a summary of the GSK Plc (GSK) Q1 2024 Earnings Call Transcript:Financial Performance:GSK reported Q1 sales of £7.4 billion, a 13% increase, and a core operating profit of £2.4 billio
GlaxoSmithKline Announces Strong Q1 and Positive 2024 Outlook
GlaxoSmithKline (GSK.US) Q1 Results Exceed Expectations and Raises Full-Year Profit Guidelines
The Zhitong Finance App learned that GlaxoSmithKline (GSK.US) announced the first quarter results on Wednesday. According to the data, the company's Q1 revenue was 7.36 billion pounds (9.18 billion US dollars), up 10% year-on-year at a fixed exchange rate (CER), higher than market expectations of £7.07 billion; earnings per share were 43.1 pence, which was also higher than market expectations of 37.3 pence. GlaxoSmithKline raised its full-year profit guidance and said sales in the first half of this year will be higher than in the second half due to strong market demand for its respiratory virus and shingles vaccines. The pharmaceutical company currently predicts that in 2024
Express News | Glaxosmithkline Sues Pfizer and BioNTech Over Mrna Technology Patents in Covid-19 Vaccines - US Court Filing
Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)
Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline, H. Lundbeck AS, Johnson & Johnson, Pfizer
New York, USA, April 16, 2024 (GLOBE NEWSWIRE) -- Global Anti-Depressant Drugs Market to Register Incremental Growth by 2030, Predicts DelveInsight | Key Companies - AbbVie, AstraZeneca, Eli Lilly and Company,
Global Dietary Supplements Market to Grow Immensely by 2030, Predicts DelveInsight | Key Companies - Amway, Abbott, Bayer, Pfizer, Otsuka, GlaxoSmithKline, American Health, Good Health New Zealand
New York, USA, April 10, 2024 (GLOBE NEWSWIRE) -- Global Dietary Supplements Market to Grow Immensely by 2030, Predicts DelveInsight | Key Companies - Amway, Abbott, Bayer, Pfizer, Otsuka, GlaxoSmithKline,
GlaxoSmithKline Executes Major Share Transfer
GlaxoSmithKline (GSK.US) Chronic Cough Treatment Launches Phase 3 Clinical Trial in China
Bellus Health has registered to launch an international multi-center (including China) phase 3 clinical study.
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods, GlaxoSmithKline and Toyota Motor.
Vaccine Research Report 2024: Global Trends, Opportunities and Competitive Analysis to 2030 Featuring GlaxoSmithKline, Merck, Pfizer, Sanofi, and CSL
Mid-term analysis of GlaxoSmithKline (GSK.US) multiple myeloma combination therapy trial yielded positive results
GlaxoSmithKline published a mid-trial analysis evaluating a combination therapy for recurrent or refractory multiple myeloma (RRMM) with positive results.
Analysts Have Conflicting Sentiments on These Healthcare Companies: EBOS Group Limited (AU:EBO), Craneware (GB:CRW) and GlaxoSmithKline (GB:GSK)
Bronchiolitis Obliterans Syndrome Market to Grow Substantially by 2032, Assesses DelveInsight | Key Players - OrphAI Therapeutics, Sanofi, Renovion, Zambon SpA, Mallinckrodt, Incyte Corporation, GlaxoSmithKline, Mereo Biopharma, Genentech
New York, USA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bronchiolitis Obliterans Syndrome Market to Grow Substantially by 2032, Assesses DelveInsight | Key Players - OrphAI Therapeutics, Sanofi, Renovion, Zambon SpA,
GlaxoSmithKline (GSK.US) settles second Zantac cancer lawsuit in California
GlaxoSmithKline (GSK.US) will settle a lawsuit brought in the US by its best-selling heartburn drug Zantac in California. This is the second such lawsuit this month.
GlaxoSmithKline (GSK.US) gonorrhea oral medication welcomes significant progress: not as effective as existing combination treatments
GlaxoSmithKline said on Monday that compared to existing combination treatments, the company's oral medication for gonorrhea met the main goal of non-poor efficacy in an important late-stage clinical trial.
Vir Biotechnology Ends Influenza Deal With GlaxoSmithKline
No Data